Leerink and Goldman Sachs are acting as joint book running managers for the offering.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCUS:
- Arcus Biosciences announces common stock offering, no amount given
- Arcus Biosciences price target raised to $16 from $14 at Goldman Sachs
- Arcus Biosciences price target raised to $35 from $33 at Wedbush
- Arcus Biosciences price target raised to $56 from $54 at Citi
- Arcus Biosciences price target raised to $28 from $24 at H.C. Wainwright
